Literature DB >> 15086928

Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States.

Shuling Li1, Robert N Foley, Allan J Collins.   

Abstract

BACKGROUND: The view that hemoglobin levels in peritoneal dialysis patients should be maintained at 11 to 12 g/dL is based largely on the results of studies in hemodialysis patients.
METHODS: We studied 13,974 erythropoietin-treated Medicare patients who initiated peritoneal dialysis between 1991 and 1998. Mean hemoglobin levels for the first 6 months of the study and, subsequently, time to first hospitalization and death during a 2-year follow-up were determined.
RESULTS: The percentages of patients with hemoglobin levels of <10, 10 to 10.9, 11 to 11.9, and >/=12 g/dL were 24.6%, 40.6%, 27.6%, and 7.2%, respectively. First-hospitalization and death rates, respectively, were 109.5 and 21.6 per 100 patient-years in nondiabetic patients, and 152.9 and 31.5 in diabetic patients. In nondiabetic patients, adjusted hospitalization hazard ratios for hemoglobin levels of <10, 10 to 10.9, 11 to 11.9 (reference category), and >/=12 g/dL were 1.29 (P < 0.0001), 1.15 (P < 0.0001), 1, and 0.98 (NS), respectively. The corresponding adjusted mortality hazard ratios were 1.43 (P < 0.0001), 1.13 (P < 0.05), 1, and 1.14 (NS). In diabetic patients, hazard ratios of 1.26 (P < 0.0001), 1.07 (NS), 1, and 0.82 (P < 0.01) were observed for hospitalization, and 1.34 (P < 0.0001), 1.18 (P < 0.01), 1, and 0.92 (NS) for mortality.
CONCLUSION: In peritoneal dialysis patients, anemia is associated with hospitalization and mortality in a manner supporting current Kidney Dialysis Outcomes Quality Initiative (K/DOQI) hemoglobin targets. In addition, hemoglobin levels of >/=12 g/dL are associated with lower hospitalization rates in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086928     DOI: 10.1111/j.1523-1755.2004.00584.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

1.  Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.

Authors:  Uyen Duong; Kamyar Kalantar-Zadeh; Miklos Z Molnar; Joshua J Zaritsky; Isaac Teitelbaum; Csaba P Kovesdy; Rajnish Mehrotra
Journal:  Am J Nephrol       Date:  2012-01-26       Impact factor: 3.754

2.  Association of hemoglobin and survival in peritoneal dialysis patients.

Authors:  Miklos Z Molnar; Rajnish Mehrotra; Uyen Duong; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

3.  Association of pre-transplant erythropoiesis-stimulating agent responsiveness with post-transplant outcomes.

Authors:  Miklos Z Molnar; Suphamai Bunnapradist; Edmund Huang; Mahesh Krishnan; Allen R Nissenson; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2012-04-12       Impact factor: 5.992

4.  Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis.

Authors:  Raja Zabaneh; Simon D Roger; Mohamed El-Shahawy; Michael Roppolo; Grant Runyan; Janet O'Neil; Ping Qiu
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

5.  Hemoglobin level and risk of hospitalization and mortality in children on peritoneal dialysis.

Authors:  Erin K Dahlinghaus; Alicia M Neu; Meredith A Atkinson; Jeffrey J Fadrowski
Journal:  Pediatr Nephrol       Date:  2014-08-10       Impact factor: 3.714

Review 6.  Slowing chronic kidney disease progression: results of prospective clinical trials in adults.

Authors:  Thai Nguyen; Robert D Toto
Journal:  Pediatr Nephrol       Date:  2008-03-07       Impact factor: 3.714

7.  Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome.

Authors:  Bassam Bernieh; Samra Abouchacra; Yousef Boobes; Mohammad R Al Hakim; Nico Nagelkerke; Ahmad Chaaban; Mohamad Ahmed; Qutaiba Hussain; Hanan El Jack; Faiz Abayechi; Imran Khan; Nicole Gebran
Journal:  Int Urol Nephrol       Date:  2014-01-22       Impact factor: 2.370

8.  Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis.

Authors:  Keiji Hirai; Hiroaki Nonaka; Moeka Ueda; Junki Morino; Shohei Kaneko; Saori Minato; Yuko Mutsuyoshi; Katsunori Yanai; Hiroki Ishii; Momoko Matsuyama; Taisuke Kitano; Akinori Aomatsu; Haruhisa Miyazawa; Kiyonori Ito; Yuichiro Ueda; Susumu Ookawara; Yoshiyuki Morishita
Journal:  Front Med (Lausanne)       Date:  2021-07-07

9.  Effective achievement of hemoglobin stability with once-monthly C.E.R.A. in peritoneal dialysis patients: a prospective study.

Authors:  Michael Koch; Wolfgang Treiber; Danilo Fliser
Journal:  Clin Drug Investig       Date:  2013-10       Impact factor: 2.859

10.  Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

Authors:  Bernard Canaud; Giulio Mingardi; Johann Braun; Pedro Aljama; Peter G Kerr; Francesco Locatelli; Giuseppe Villa; Bruno Van Vlem; Alan W McMahon; Cécile Kerloëguen; Ulrich Beyer
Journal:  Nephrol Dial Transplant       Date:  2008-06-27       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.